Form 4: Avalo Therapeutics Director Jonathan Goldman Granted Stock Options

Avalo Therapeutics, Inc. Director Jonathan Goldman was granted 20,100 stock options with an exercise price of $4.47, vesting on the first anniversary of the grant date.

Summary

• Jonathan Goldman, a Director of Avalo Therapeutics, Inc. (AVTX), was granted 20,100 stock options on June 17, 2025.
• The stock options have an exercise price of $4.47 per share.
• These options are scheduled to vest 100% on June 17, 2026, which marks the first anniversary of the grant date, contingent upon Mr. Goldman's continued service to the company.
• The granted stock options have an expiration date of June 17, 2035.

Sentiment

Score: 6

Explanation: The document reports a routine grant of stock options to a director, which is a standard compensation practice aimed at aligning management interests with shareholder value. It does not contain information that would significantly alter the company's financial outlook or operational status, thus indicating a neutral to slightly positive sentiment.

Positives

• The grant of 20,100 stock options to Director Jonathan Goldman aligns his financial interests with those of shareholders, incentivizing long-term performance and value creation for Avalo Therapeutics.

Future Outlook

The stock options granted to Director Jonathan Goldman are set to vest 100% on June 17, 2026, contingent on his continued service, indicating a future incentive for his ongoing involvement with the company and a long-term commitment through the option's expiration in 2035.

Industry Context

The granting of stock options to directors is a common and established practice within the biotechnology and pharmaceutical industry, serving as a standard component of executive and director compensation packages. This mechanism is widely used to align the interests of leadership with long-term shareholder value creation and to retain key talent.

Comparison to Industry Standards

• The grant of stock options with a vesting period is a standard compensation mechanism for directors in publicly traded companies, particularly within the biotech sector, aiming to incentivize long-term commitment and performance.
• While the specific value and number of options granted are unique to this individual and company, the structure of the compensation (options with a vesting schedule) is consistent with typical industry practices for director remuneration.

Related Party Transactions

• Grant of 20,100 stock options to Jonathan Goldman, a Director of Avalo Therapeutics, Inc., representing a transaction between the company and a related party (director).

Stakeholder Impact

• Shareholders: The grant of stock options is intended to align the director's interests with those of shareholders, potentially leading to improved long-term company performance. However, future exercise of these options could result in minor share dilution.
• Employees: No direct impact on general employees is indicated by this filing.
• Customers: No direct impact on customers is indicated by this filing.
• Suppliers: No direct impact on suppliers is indicated by this filing.
• Creditors: No direct impact on creditors is indicated by this filing.

Next Steps

• The stock options granted to Jonathan Goldman are scheduled to vest on June 17, 2026, subject to his continued service.

Key Dates

Recommendation

Keywords

Avalo Therapeutics, AVTX, stock options, director compensation, SEC Form 4, beneficial ownership, equity compensation